International Journal of Hematology

, Volume 80, Issue 3, pp 246–249 | Cite as

Humanized Anti-Interleukin 6 Receptor Antibody Induced Long-term Remission in a Patient with Life-Threatening Refractory Autoimmune Hemolytic Anemia

  • Akane Kunitomi
  • Yoshiteru Konaka
  • Masato Yagita
  • Kiyoshi Takatsuki
  • Norihiro Nishimoto
  • Tadamitsu Kishimoto
Case Report

Abstract

Refractory autoimmune hemolytic anemia (AIHA) is associated with considerable rates of mortality. Interleukin 6 (IL-6) has been reported to play a role in the pathogenesis of AIHA. This report describes a patient with AIHA who was successfully treated with a humanized anti-human IL-6 receptor (IL-6R) monoclonal antibody (MoAb). He had experienced life-threatening AIHA and had received conventional therapy with corticosteroids, azathioprine, cyclophosphamide, cyclosporin A, melphalan, plasma exchange, and irradiation to his spleen. However, the patient’s symptoms and laboratory data did not show a sufficient improvement. Because his serum IL-6 level was elevated, we attempted to block IL-6 signaling by using a humanized anti-IL-6R MoAb, MRA.With 8 mg/kg of MRA administration every 2 weeks, the serum hemoglobin level gradually increased and normalized within 4 months. After 2 years of MRA treatment, the disease activity was well controlled without adverse reactions. Anti-IL-6R MoAb can be a novel and effective therapeutic agent for AIHA.

Key words

AIHA IL-6 Humanized anti-IL-6 receptor antibody 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Claire H. Autoimmune hemolytic anemia. Clin Rev Allergy Immunol. 1998;16:285–295.CrossRefGoogle Scholar
  2. 2.
    Bradley CG, Richard CF. Autoimmune hemolytic anemia. Am J Hematol. 2002;69:258–271.CrossRefGoogle Scholar
  3. 3.
    Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia. 2002;16:2092–2095.CrossRefPubMedGoogle Scholar
  4. 4.
    Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B. Anti-CD20 monoclonal antibody (rituximab) for lifethreatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol. 2002;116:465–467.CrossRefPubMedGoogle Scholar
  5. 5.
    Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol Today. 1990;11:443–449.CrossRefPubMedGoogle Scholar
  6. 6.
    Hirano T. Interleukin 6 and autoimmunity and plasma cell neoplasias. Res Immunol. 1992;143:759–763.CrossRefPubMedGoogle Scholar
  7. 7.
    Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002;46:3143–3150.CrossRefPubMedGoogle Scholar
  8. 8.
    Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med. 2000;6:583–588.CrossRefPubMedGoogle Scholar
  9. 9.
    Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still’s disease. Arthritis Rheum. 2002;46:3388–3389.CrossRefPubMedGoogle Scholar
  10. 10.
    Barcellini W, Clerici G, Montesano R, et al. In vitro quantificationo f anti-red blood cell antibody production in idiopathic autoimmune haemolytic anaemia: effect of mitogen and cytokine stimulation. Br J Haematol. 2000;111:452–460.CrossRefPubMedGoogle Scholar
  11. 11.
    Barcellini W, Montesano R, Clerici G, et al. In vitro production of anti-RBC antibodies and cytokines in chronic lymphocytic leukemia. Am J Hematol. 2002;71:177–183.CrossRefPubMedGoogle Scholar
  12. 12.
    Lapierre Y, et al.The gel test: a new way to detect red cell antigenantibody reactions. Transfusion. 1990;30:109–113.CrossRefPubMedGoogle Scholar
  13. 13.
    Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56–61.PubMedGoogle Scholar
  14. 14.
    Schuerwegh AJ, Van Offel JF, Stevens WJ, Bridts CH, De Clerck LS. Influence of therapy with chimeric monoclonal tumour necrosis factor-α antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. Rheumatology (Oxford). 2003;42:541–548.CrossRefPubMedGoogle Scholar
  15. 15.
    Sun Y, Chen HM, Subudhi SK, et al. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med. 2002;8:1405–1413.CrossRefPubMedGoogle Scholar
  16. 16.
    Monteleone G, MacDonald TT. Manipulation of cytokines in the management of patients with inflammatory bowel disease. Ann Med. 2000;32:552–560.CrossRefPubMedGoogle Scholar
  17. 17.
    Stasi R, Pagano A, Stipa E, Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood. 2002;99:3872–3873.CrossRefPubMedGoogle Scholar
  18. 18.
    Weide R, Heymanns J, Pandorf A,Koppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus. 2003;12:779–782.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  • Akane Kunitomi
    • 1
  • Yoshiteru Konaka
    • 1
  • Masato Yagita
    • 1
  • Kiyoshi Takatsuki
    • 1
  • Norihiro Nishimoto
    • 2
  • Tadamitsu Kishimoto
    • 2
  1. 1.aDivision of Hematology and Rheumatology Department of Medicine, Kitano HospitalThe Tazuke Kofukai Medical Research InstituteKita-ku, OsakaJapan
  2. 2.Laboratory of Immune RegulationGraduate School of Frontier Biosciences, Osaka UniversityOsakaJapan

Personalised recommendations